ASCO: As FDA’s Zolbetuximab Decision Looms, Astellas Looks To Meet Testing Challenge

Scrip sat down with Astellas chief medical officer Tadaaki Taniguchi to talk about the drug maker’s plans for taking its Claudin18.2-targeting drug to the US market.